Haier Biomedical Hosts European Partner Summit in Rome and Advances "In Europe, for Europe" Strategy

Haier Biomedical Hosts European Partner Summit in Rome and Advances "In Europe, for Europe" Strategy

ROME, March 11, 2026 /PRNewswire/ -- Haier Biomedical recently convened its European Partner Summit in Rome under the theme "Advancing Together - Sharing the Future of Biomedical Innovation," which brought together 37 regional partners and industry...

Advanced Hybrid Technology Empowers the "Travel+" Strategy -- JETOUR T2 PHEV Leads the Hybrid Off-Road Segment

Advanced Hybrid Technology Empowers the "Travel+" Strategy -- JETOUR T2 PHEV Leads the Hybrid Off-Road Segment

WUHU, China, Feb. 26, 2026 /PRNewswire/ -- In recent years, JETOUR's T Series has delivered excellent results in the light off-road segment worldwide. In 2025 alone, the global sales of the T Series exceed 300,000 units. In markets such as the UAE,...

Entering Its 16th Year: Vantage Markets Sets a New Standard for the "Ultimate Trading Machine"

Entering Its 16th Year: Vantage Markets Sets a New Standard for the "Ultimate Trading Machine"

PORT VILA, Vanuatu, Jan. 13, 2026 /PRNewswire/ -- For Vantage Markets, 2025 marked not only the company's 16th year in operation, but also a significant milestone in its brand evolution. Founded in 2009, Vantage has grown from an industry challenger...

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy

Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All": — A subanalysis of...

NetDragon Expands Global "AI + Education" Strategy, Partners with Thailand MHESI to Launch AI Education Platform

NetDragon Expands Global "AI + Education" Strategy, Partners with Thailand MHESI to Launch AI Education Platform

HONG KONG, May 22, 2025 /PRNewswire/ -- NetDragon Websoft Holdings Limited ("NetDragon" or the "Company"; Hong Kong Stock Code: 0777), a global leader in building internet communities, is pleased to announce the official launch of the MHESI Skill...

Qian Fenglei Restructures Capital Market with "FO-X" Strategy: Acquires 600 Million HKD Stake to Take Control of WellCell, Aiming for Trillion-Dollar Web3 Ecosystem

Qian Fenglei Restructures Capital Market with "FO-X" Strategy: Acquires 600 Million HKD Stake to Take Control of WellCell, Aiming for Trillion-Dollar Web3 Ecosystem

HONG KONG, May 9, 2025 /PRNewswire/ -- When traditional capital meets the Web3.0 wave, a disruptive capital experiment is quietly unfolding in Hong Kong's stock market. On May 9, 2025, WellCell (02477.HK), a Hong Kong-listed company, announced that...

BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (Nasdaq: BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of...

Registration Open: CBD Guangzhou 2025 to Showcase Innovation in Building Decoration with 'Three-Ecology' Strategy

Registration Open: CBD Guangzhou 2025 to Showcase Innovation in Building Decoration with 'Three-Ecology' Strategy

GUANGZHOU, China, March 26, 2025 /PRNewswire/ -- The 27th China (Guangzhou) International Building Decoration Fair (CBD Guangzhou 2025) is set to take place from July 8-11, 2025, at the Canton Fair Complex and Poly World Trade Expo Center (PWTC) in...

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and...

menu
menu